<DOC>
	<DOC>NCT01012310</DOC>
	<brief_summary>The purpose of this study is to determine the safety and toleration of single and multiple doses of PF-04531083. (To investigate the plasma and urinary pharmacokinetics of PF-04531083 and its metabolites, following single and multiple dose administration in healthy male and/or female subjects; and to determine whether PF-04531083 raises levels of enzymes involved in metabolism of other drugs following multiple dosing).</brief_summary>
	<brief_title>Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects btween the ages of 1855 years Body Mass Index (BMI) of 15.5 to 30.5 and a total body weight greater than 50kg (110 lbs). Evidence or history of clinically signifcant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. A positive urine drug screen. History of regular alcohol consumption exceeding 21 drinks/week within 6 months of screening Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. Pregnant or nursing females; females of childbearing potentioal who are unwilling or unable to use an acceptable method on contraception.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>pharmacokinetics safety tolerability multiple dosing</keyword>
</DOC>